The challenges of host and viral diversity in HIV vaccine design

Current Opinion in Immunology

Volumn 18, Issue 4, 2006, Pages 430-437

  Brander, Christian ^a   Frahm, Nicole ^a   Walker, Bruce D ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; BIOINFORMATICS; CELLULAR IMMUNITY; CORRELATION ANALYSIS; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS REPLICATION;

AIDS VACCINES; HIV; HIV INFECTIONS; HUMANS; VARIATION (GENETICS);

EID: 33745339957     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.05.012     Document Type: Review

References (86)

1. Frahm N., Korber B.T., Adams C.M., Szinger J.J., Draenert R., Addo M.M., Feeney M.E., Yusim K., Sango K., Brown N.V., et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78 (2004) 2187-2200
2. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., Johnston M.N., Corcoran C., Wurcel A.G., Fitzpatrick C.A., et al. Comprehensive epitope analysis of HIV-1-specific T cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77 (2003) 2081-2092
3. + T cells in primary HIV-1 infection. J Virol 77 (2003) 6867-6878
4. + responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol 73 (1999) 7108-7116
5. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3 (2002) 1061-1068
6. + memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 198 (2003) 947-955
7. + T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol 77 (2003) 10900-10909
8. + T cells. J Exp Med 200 (2004) 701-712
9. + T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur J Immunol 35 (2005) 159-170
10. + T-cells. Blood 2006. in press. Extensive multi-color flow cytometry was used to assess the functional profile of HIV-specific CD8 T cells in HIV controllers and non-controllers. Cells with simultaneous production of IFN-γ, IL-2, TNF-α and MIP-1β and the ability to degranulate (CD107 expression) were preferentially detected in individuals who have controlled HIV infection. These observations were not caused by an increase of memory cells in the controlling subjects because memory phenotype was not predictive of functionality. In addition, defects in functionality were only modestly restored with short-term (up to one year) anti-retroviral treatment.
11. Champagne P., Ogg G.S., King A.S., Knabenhans C., Ellefsen K., Nobile M., Appay V., Rizzardi G.P., Fleury S., Lipp M., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410 (2001) 106-111
12. Hess C., Means T.K., Autissier P., Woodberry T., Altfeld M., Addo M.M., Frahm N., Brander C., Walker B.D., and Luster A.D. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood 104 (2004) 3463-3471
13. + T cells with an effector phenotype and control of viral replication. Lancet 363 (2004) 863-866
14. Zimmerli S.C., Harari A., Cellerai C., Vallelian F., Bart P.A., and Pantaleo G. HIV-1-specific IFN-γ/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 102 (2005) 7239-7244
15. Yang O.O., Ferbas J.J., Hausner M.A., Hultin L.E., Hultin P.M., McFadden D., Sawicki M., Detels R., Majchrowicz M., Matud J.L., et al. Effects of HIV-1 infection on lymphocyte phenotypes in blood versus lymph nodes. J Acquir Immune Defic Syndr 39 (2005) 507-518
16. + T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 79 (2005) 9228-9235
17. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200 (2004) 749-759
18. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200 (2004) 761-770
19. Woodberry T., Suscovich T.J., Henry L.M., August M., Waring M.T., Kaur A., Hess C., Kutok J.L., Aster J.C., Wang F., et al. αEβ7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population. J Immunol 175 (2005) 4355-4362
20. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K.J., Hilton L., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432 (2004) 769-775
21. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K, Woodberry T, Sango K, Hewitt HS, Henry LM et al.: Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006. in press.
22. Boon A.C., De Mutsert G., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., and Rimmelzwaan G.F. Preferential HLA usage in the influenza virus-specific CTL response. J Immunol 172 (2004) 4435-4443
23. + T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64 (2003) 440-452
24. Frahm N., Adams S., Kiepiela P., Linde C.H., Hewitt H.S., Lichterfeld M., Sango K., Brown N.V., Pae E., Wurcel A.G., et al. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 79 (2005) 10218-10225
25. Frahm N., Kiepiela P., Adams S., Linde C.H., Hewitt H.S., Sango K., Feeney M.E., Addo M.M., Lichterfeld M., Lahaie M.P., et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7 (2006) 173-178. HLA-B*1503 was found to be associated with low HIV viral loads in a cohort of HIV clade B infection in the USA, in which the HLA-B*1503 allele frequency in the general population was below 1.5%. In contrast, HLA-B*1503-expressing individuals in a clade C infected cohort in Durban (which had an allele frequency of 13%) presented with higher viral loads than the rest of the cohort. The dominant CTL targets were shared between the two cohorts, indicating that subdominant CTL populations preferentially present in clade B-infected subjects were mediating the beneficial effects. Analysis of HIV clade B and C sequences showed frequent mutations consistent with CTL escape in the clade C but not the clade B sequences of these subdominant epitopes, suggesting that high allele frequency might facilitate the elimination of protective CTL epitopes for the locally circulating viral populations.
26. O'Brien S.J., Gao X., and Carrington M. HLA and AIDS: a cautionary tale. Trends Mol Med 7 (2001) 379-381
27. Trachtenberg E.A., and Erlich H.A. A review of the role of the human leukocyte antigen (HLA) system as a host immunogenic factor influencing HIV transmission and progression to AIDS. In: Korber B.T.K., Brander C., Haynes B.F., Moore J.P., Koup R.A., Kuiken C., Walker B.D., and Watkins D.I. (Eds). HIV Molecular Immunology 2001 (2001), Theoretical Biology and Biophysics Group 143-160
28. Kesmir C, Borghans J, de Boer RJ: HLA molecules targeting the conserved HIV-1 p24 protein are associated with slow progression to AIDS. In The 12th International Workshop on HIV Dynamics and Evolution; Cleveland, OH: 2005.
29. Scherer A., Frater J., Oxenius A., Agudelo J., Price D.A., Gunthard H.F., Barnardo M., Perrin L., Hirschel B., Phillips R.E., et al. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci USA 101 (2004) 12266-12270
30. + lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype. J Virol 79 (2005) 14887-14898
31. Messaoudi I., Guevara Patino J.A., Dyall R., LeMaoult J., and Nikolich-Zugich J. Direct link between MHC polymorphism, T cell avidity, and diversity in immune defense. Science 298 (2002) 1797-1800
32. + T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76 (2002) 2298-2305
33. Novitsky V., Gilbert P., Peter T., McLane M.F., Gaolekwe S., Rybak N., Thior I., Ndung'u T., Marlink R., Lee T.H., et al. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 77 (2003) 882-890
34. Zuniga R., Lucchetti A., Galvan P., Sanchez S., Sanchez C., Hernandez A., Sanchez H., Frahm N., Linde C.H., Hewitt H.S., et al. Preferential CTL targeting of HIV gag is associated with relative control of HIV infection. J Virol 80 (2006) 3122-3125. A novel look at the distribution of HIV-specific CTL responses in a Peruvian and in a US-based cohort of clade B infection. This showed that their relative focus on Gag-derived peptides was associated with better viral control. Whereas the absolute magnitude and breadth of the Gag-specific response might not always correspond to effective viral control, the data indicate that the more that the cellular immune system focuses on Gag targets, the better viral replication is controlled in vivo.
35. + cell responses. J Infect Dis 192 (2005) 1588-1596
36. + T cells: correlation with viral load. J Virol 78 (2004) 3233-3243
37. + cells: evidence for HLA class 1-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71 (1997) 3120-3128
38. Yang O.O., Sarkis P.T., Ali A., Harlow J.D., Brander C., Kalams S.A., and Walker B.D. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med 197 (2003) 1365-1375
39. + T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay. J Virol 79 (2005) 14986-14991. In vitro viral (SIV) replication inhibition assays were used to assess potential differences between Gag- and Tat-specific CTL populations in their ability to control viral replication. Short-term in vitro expanded Tat-specific cells showed superior in vitro control of viral replication compared with Gag-specific cells. This difference might be associated with the earlier expression of the tat compared with gag genes during viral replication, and with the higher functional avidity of the Tat- versus Gag-specific CTL.
40. Wick W.D., Yang O.O., Corey L., and Self S.G. How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?. J Virol 79 (2005) 13579-13586
41. + central memory T cells in protection from simian AIDS. J Immunol 175 (2005) 3502-3507
42. + T cell responses. Eur J Immunol 35 (2005) 2532-2540
43. Gupta S., Janani R., Bin Q., Luciw P., Greer C., Perri S., Legg H., Donnelly J., Barnett S., O'Hagan D., et al. Characterization of human immunodeficiency virus gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol 79 (2005) 7135-7145
44. ••], HIV disease progression was more accelerated than expected for an HLA-B27-expressing subject.
45. Seaman M.S., Peyerl F.W., Jackson S.S., Lifton M.A., Gorgone D.A., Schmitz J.E., and Letvin N.L. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 78 (2004) 206-215
46. Santra S., Barouch D.H., Korioth-Schmitz B., Lord C.I., Krivulka G.R., Yu F., Beddall M.H., Gorgone D.A., Lifton M.A., Miura A., et al. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci USA 101 (2004) 11088-11093
47. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., Tang Y., Holmes E.C., Allen T., Prado J.G., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10 (2004) 282-289
48. Leslie A., Kavanagh D., Honeyborne I., Pfafferott K., Edwards C., Pillay T., Hilton L., Thobakgale C., Ramduth D., Draenert R., et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 201 (2005) 891-902
49. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., and Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296 (2002) 1439-1443
50. + cytotoxic T lymphocyte response. J Exp Med 200 (2004) 1243-1256
51. + T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol 175 (2005) 4618-4626
52. Yokomaku Y., Miura H., Tomiyama H., Kawana-Tachikawa A., Takiguchi M., Kojima A., Nagai Y., Iwamoto A., Matsuda Z., and Ariyoshi K. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 78 (2004) 1324-1332
53. Draenert R., Le Gall S., Pfafferott K.J., Leslie A.J., Chetty P., Brander C., Holmes E.C., Chang S.C., Feeney M.E., Addo M.M., et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 199 (2004) 905-915
54. Allen T.M., Altfeld M., Yu X.G., O'Sullivan K.M., Lichterfeld M., Le Gall S., John M., Mothe B.R., Lee P.K., Kalife E.T., et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 78 (2004) 7069-7078
55. Frahm N., Korber B.T., and Brander C. Optimal CTL epitope identification in HIV clade B and non-clade B infection. In: Korber B.T., Brander C., Haynes B.F., Koup R., Moore J.P., Walker B.D., and Watkins D.I. (Eds). HIV Immunology and HIV/SIV Vaccine Databases 2004 (2004), Theoretical Biology and Biophysics, Los Alamos National Laboratory 3-20
56. + T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 79 (2005) 12952-12960
57. Haas G., Plikat U., Debre P., Lucchiari M., Katlama C., Dudoit Y., Bonduelle O., Bauer M., Ihlenfeldt H.G., Jung G., et al. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol 157 (1996) 4212-4221
58. Friedrich T.C., Dodds E.J., Yant L.J., Vojnov L., Rudersdorf R., Cullen C., Evans D.T., Desrosiers R.C., Mothe B.R., Sidney J., et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 10 (2004) 275-281
59. Fernandez C.S., Stratov I., De Rose R., Walsh K., Dale C.J., Smith M.Z., Agy M.B., Hu S.L., Krebs K., Watkins D.I., et al. Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 79 (2005) 5721-5731
60. + T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79 (2005) 13239-13249
61. Peyerl F.W., Bazick H.S., Newberg M.H., Barouch D.H., Sodroski J., and Letvin N.L. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol 78 (2004) 13901-13910
62. Barouch D.H., Powers J., Truitt D.M., Kishko M.G., Arthur J.C., Peyerl F.W., Kuroda M.J., Gorgone D.A., Lifton M.A., Lord C.I., et al. Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat Immunol 6 (2005) 247-252. Analysis of sequentially transmitted SIV in MHC-matched animals led to a transient reversion of the initial escape variant within weeks of infection. This restored immunogenic epitope sequence induced wild-type-specific CTL responses from which the virus subsequently escaped again.
63. Kijak G.H., Currier J.R., Tovanabutra S., Cox J.H., Michael N.L., Wegner S.A., Birx D.L., and McCutchan F.E. Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. AIDS Rev 6 (2004) 54-60
64. Kelleher A.D., Long C., Holmes E.C., Allen R.L., Wilson J., Conlon C., Workman C., Shaunak S., Olson K., Goulder P., et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 193 (2001) 375-386
65. Betts M.R., Krowka J., Santamaria C., Balsamo K., Gao F., Mulundu G., Luo C., N'Gandu N., Sheppard H., Hahn B.H., et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol 71 (1997) 8908-8911
66. Durali D., Morvan J., Letourneur F., Schmitt D., Guegan N., Dalod M., Saragosti S., Sicard D., Levy J.P., and Gomard E. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 72 (1998) 3547-3553
67. + cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses 14 (1998) 925-937
68. Ferrari G., Humphrey W., McElrath M.J., Excler J.L., Duliege A.M., Clements M.L., Corey L.C., Bolognesi D.P., and Weinhold K.J. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 94 (1997) 1396-1401
69. Coplan P.M., Gupta S.B., Dubey S.A., Pitisuttithum P., Nikas A., Mbewe B., Vardas E., Schechter M., Kallas E.G., Freed D.C., et al. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 191 (2005) 1427-1434. Comprehensive study of cross-reactivity against clade A, B and C peptide pools spanning Gag, Nef, Pol, Rev and Tat. 250 HIV-infected individuals from Brazil (mostly clade B), Malawi and South Africa (mostly clade C), Thailand (mostly CRF01_AE) and the USA (clade B) were tested in an IFN-γ ELISpot assay. More than 95% of all study subjects showed responses to clade B Gag and/or Nef, irrespective of the infecting clade. Significantly higher (p < 0.0001) cross-clade reactivity was detected for Nef (ratio 0.97) than for Gag (ratio 0.67). The data suggest that a vaccine based on a single clade - if able to induce strong cellular immune responses - could be broadly effective, irrespective of the genotype prevalent in the target population.
70. Geels M.J., Dubey S.A., Anderson K., Baan E., Bakker M., Pollakis G., Paxton W.A., Shiver J.W., and Goudsmit J. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol 79 (2005) 11247-11258. Assessment of cross-reactivity in ten non-clade B-infected individuals against clade B peptide pools spanning Gag, Pol, Nef, Rev and Tat. Nine subjects responded to clade B peptides, preferentially targeting Gag and Nef. All nine subjects that responded to clade B Gag also recognized both clade A and C Gag peptide pools, whereas six of seven subjects that responded to clade B Nef also targeted both clade A and C Nef peptide pools. The cross-clade reactivity was inversely correlated with the genetic distance between the autologous amino acid and the peptide sequence.
71. Ferrari G., Currier J.R., Harris M.E., Finkelstein S., de Oliveira A., Barkhan D., Cox J.H., Zeira M., Weinhold K.J., Reinsmoen N., et al. HLA-A and -B allele expression and ability to develop anti-gag cross-clade responses in subtype C HIV-1-infected ethiopians. Hum Immunol 65 (2004) 648-659
72. + T-cell responses with a preference for the predominant circulating clade. J Acquir Immune Defic Syndr 40 (2005) 245-249
73. + T cells of HIV type 1 CRF02_AG-infected Ivorian (west Africa). AIDS Res Hum Retroviruses 21 (2005) 620-628
74. Francois-Bongarcon V., Feng Y., Lee S.K., Chen G., Shankar P., Liu Y., Tao X., Shao Y., and Lieberman J. Cross-clade CD8 T-cell responses to HIV(IIIB) and chinese B' and C/B' viruses in north American and Chinese HIV-seropositive donors. J Acquir Immune Defic Syndr 37 (2004) 1435-1444
75. Sabado R.L., Kilpatrick S., Ali A., Dagarag M., Ng H.L., Cao H., and Yang O.O. Detection of HIV-1-specific CTL responses in clade B infection with clade C peptides and not clade B consensus peptides. J Immunol Methods 296 (2005) 1-10
76. Frahm N, Linde CH, Hewitt HS, Brown NV, Nickle DC, Zaman MT, Pae E, Zuniga R, Sanchez J, Lucchetti A et al.: T cell responses to artificial clade B, clade C and group M sequences in different ethinicities: implications for vaccine development. In AIDS Vaccine 2005; Montreal, Quebec: 2005.
77. Bansal A., Gough E., Ritter D., Wilson C., Mulenga J., Allen S., and Goepfert P.A. Group M-based HIV-1 gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients. AIDS 20 (2006) 353-360. This study reports a comparison of clade-specific and group-M-based Gag consensus and ancestral sequences in 43 clade B- and 13 clade C-infected individuals. Nearly 70% of peptides were completely cross-reactive for all tested peptide sets (consensus A, B, C, M, ancestral B, M and HXB2) in at least one clade B-infected subject, and recognition of only one peptide was limited to a single peptide set. Nearly 90% of responses against consensus B, M and HXB2 were detected using all three peptide sets in clade B infection. In clade C-infected subjects, 100% of the nine detected responses were seen using consensus C and M, of which eight were also recognized in consensus A and B as well as HXB2. Overall, consensus and ancestral M sequences were able to detect the majority of responses in both clade B- and clade C-infected subjects, suggesting the usefulness of central sequences for both detection and induction of cross-reactive T cell responses.
78. Rutebemberwa A., Currier J.R., Jagodzinski L., McCutchan F., Birx D., Marovich M., and Cox J.H. HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. AIDS 19 (2005) 1165-1172
79. De Rose R., Chea S., Dale C.J., Reece J., Fernandez C.S., Wilson K.M., Thomson S., Ramshaw I.A., Coupar B.E., Boyle D.B., et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 23 (2005) 1949-1956
80. Amara R.R., Sharma S., Patel M., Smith J.M., Chennareddi L., Herndon J.G., and Robinson H.L. Studies on the cross-clade and cross-species conservation of HIV-1 gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques. Virology 334 (2005) 124-133
81. Smith J.M., Amara R.R., Wyatt L.S., Ellenberger D.L., Li B., Herndon J.G., Patel M., Sharma S., Chennareddi L., Butera S., et al. Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses. AIDS Res Hum Retroviruses 21 (2005) 140-144
82. + T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 79 (2005) 393-400
83. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., Sambor A., Chakrabarti B.K., Huang Y., Bailer R., et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79 (2005) 2956-2963. In a large multi-arm study that included 30 rhesus monkeys, a prime-boost vaccine strategy including SIV gag and polymerase and mono- or multi-clade HIV envelope sequences was analyzed. Vaccination with single clade B, single clade C or multiclade A+B+C Env resulted in T cell responses of comparable magnitude to the immunogen(s), which suggests that immunization with complex antigens does not lead to antigenic interference. Animals were challenged with SHIV-89.6P, with a significant reduction in peak viral load for all vaccinated groups, but no additional benefit was conferred by the multiclade approach.
84. Korber BT, Frahm N, Yusim K, Fischer W, Walker BD, Brander C: T cell vaccine and peptide reagent design based on restricted patterns of variation in conservd HIV proteins. In AIDS Vaccine 2005; Montreal, Canada: 2005.
85. Korber BT: Eleventh annual bernard fields memorial lecture: global HIV-1 variation and its implications for vaccine design. In 13th Conference on Retroviruses and Opportunistic Infections; Denver, CO: 2006.
86. Jojic N, Jojic V, Heckerman D, Kadie C, Meek C, Moore C, John M, Mallal S: HLA-driven optimization of an HIV vaccine immunogen. In 12th Conference on Retroviruses and Opportunistic Infections; Boston, MA: 2005.